HDT Bio Receives ARPA-H GIVE Award to Lead Development of Automated, Point-of-Care Manufacturing for Personalized RNA Medicines
Award of up to $39.5 million funds a closed, end-to-end RNA manufacturing and quality-control platform; program includes a personalized cancer immunotherapy demonstration with Houston Methodist Research Institute and marks HDT Bio's expansion into personalized cancer medicine SEATTLE,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.